We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
APIXABAN-TEVA (Teva Pharma Australia Pty Ltd)
Product name
APIXABAN-TEVA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
138 (255 working days)
Active ingredients
apixaban
Registration type
New generic medicine
Indication
APIXABAN-TEVA is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery.
APIXABAN-TEVA is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.
APIXABAN-TEVA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients.
APIXABAN-TEVA is indicated for the prevention of recurrent DVT and PE in adult patients.